1. Home
  2. DERM vs KZIA Comparison

DERM vs KZIA Comparison

Compare DERM & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Journey Medical Corporation

DERM

Journey Medical Corporation

N/A

Current Price

$4.98

Market Cap

190.3M

Sector

Health Care

ML Signal

N/A

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

N/A

Current Price

$8.17

Market Cap

186.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DERM
KZIA
Founded
2014
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
186.7M
IPO Year
2021
2002

Fundamental Metrics

Financial Performance
Metric
DERM
KZIA
Price
$4.98
$8.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$13.75
★ $29.63
AVG Volume (30 Days)
178.1K
★ 201.6K
Earning Date
11-11-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 34.72
N/A
EPS
N/A
★ N/A
Revenue
★ $61,858,000.00
N/A
Revenue This Year
$25.29
N/A
Revenue Next Year
$50.00
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 10.20
N/A
52 Week Low
$4.31
$4.86
52 Week High
$9.56
$17.40

Technical Indicators

Market Signals
Indicator
DERM
KZIA
Relative Strength Index (RSI) 34.52 43.73
Support Level $4.84 $6.72
Resistance Level $5.50 $14.85
Average True Range (ATR) 0.34 0.72
MACD -0.03 0.14
Stochastic Oscillator 15.91 60.21

Price Performance

Historical Comparison
DERM
KZIA

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: